Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Erbium Metallicum
Generic Name
Erbium Metallicum
Active Ingredient
ErbiumCategory
Standardized Chemical Allergen [EPC]
Variants
8
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 30 [hp_C]/1 | PELLET | ORAL | 37662-0697 |
| 100 [hp_C]/1 | PELLET | ORAL | 37662-0698 |
| 1 [hp_M]/1 | PELLET | ORAL | 37662-0701 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Erbium Metallicum, you must consult a qualified healthcare professional.
| 1 [hp_Q]/1 | PELLET | ORAL | 37662-0702 |
| 500 [hp_C]/1 | PELLET | ORAL | 37662-0700 |
| 6 [hp_C]/1 | PELLET | ORAL | 37662-0695 |
| 200 [hp_C]/1 | PELLET | ORAL | 37662-0699 |
| 12 [hp_C]/1 | PELLET | ORAL | 37662-0696 |
Detailed information about Erbium Metallicum
Erbium is a multifaceted chemical agent used primarily as a standardized allergen and an acetylcholine release inhibitor. It plays a critical role in diagnostic allergy testing and neuromuscular pharmacology.
The dosage of Erbium is highly specialized and depends entirely on the intended clinical use. There is no standard 'daily dose' for Erbium as it is not a traditional maintenance medication.
Erbium is not currently FDA-approved for use in pediatric populations for allergy testing or neuromuscular inhibition. Safety and efficacy have not been established in patients under the age of 18. If a healthcare provider determines that Erbium testing is necessary for a child, the dose is typically adjusted based on body surface area (BSA), but this is considered an off-label use.
Because Erbium is primarily cleared by the kidneys, patients with a glomerular filtration rate (GFR) below 60 mL/min/1.73m² require significant caution.
No specific dosage adjustments are required for patients with hepatic impairment when using topical forms. For systemic use, monitoring of biliary excretion markers is recommended, as a portion of the drug is eliminated via the gallbladder.
Elderly patients (over 65 years) may have age-related declines in renal function. Healthcare providers typically perform a baseline creatinine clearance test before administering systemic Erbium. For topical allergy testing, no adjustment is usually necessary unless the skin barrier is significantly compromised.
Erbium is never self-administered by the patient. It must be administered by a qualified healthcare professional.
As Erbium is typically administered as a single diagnostic event or in a clinical setting, missed doses are rare. If a patch test appointment is missed, it should be rescheduled as soon as possible. If a systemic dose is interrupted, the healthcare provider will determine if the infusion should be restarted based on the patient's current neuromuscular status.
An overdose of Erbium, particularly via systemic routes, can lead to serious complications related to its mechanism as an acetylcholine release inhibitor and calcium antagonist.
> Important: Follow your healthcare provider's dosing instructions. Do not attempt to use Erbium-containing products without medical guidance.
The most common side effects of Erbium are associated with its use as a topical allergen in patch testing. These are generally localized and self-limiting.
When Erbium is absorbed systemically or used in higher concentrations, the following may occur:
Erbium is a potent chemical agent that must be handled with care. Its primary risk factors involve its ability to interfere with calcium-dependent processes and its potential to trigger severe immune responses in sensitized individuals. Patients should be screened for any history of metal allergies before undergoing Erbium-based testing.
There are currently no FDA black box warnings for Erbium. However, clinical guidelines emphasize that it should only be administered in facilities equipped with emergency resuscitation equipment due to the theoretical risk of anaphylaxis and neuromuscular blockade.
Erbium must NEVER be used in the following circumstances:
Erbium is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies of Erbium in pregnant women. Animal reproduction studies have shown that lanthanides can cross the placental barrier and may accumulate in fetal skeletal tissue.
It is unknown whether Erbium is excreted in human milk. However, many metals and lanthanides are known to pass into breast milk in small quantities. Because of the potential for serious adverse reactions in nursing infants—specifically related to neuromuscular development—a decision should be made whether to discontinue nursing or to forgo the drug, taking into account the importance of the drug to the mother.
Erbium (Er3+) functions primarily as a calcium biomimetic and antagonist. At the neuromuscular junction, it targets the P/Q-type voltage-gated calcium channels. By binding to the oxygen-coordinated sites within these channels with a higher affinity than Ca2+, Erbium prevents the influx of calcium into the presynaptic neuron. This lack of calcium prevents the activation of the SNARE complex, which is required for synaptic vesicle docking and the subsequent release of acetylcholine into the synaptic cleft. This makes Erbium a potent Acetylcholine Release Inhibitor [MoA].
Common questions about Erbium Metallicum
Erbium is primarily used in medicine as a standardized chemical allergen for diagnostic patch testing to identify metal hypersensitivities. It is also classified as an acetylcholine release inhibitor, meaning it can be used in specialized clinical settings to study or induce neuromuscular blockade. In addition to these uses, Erbium is the active medium in certain surgical lasers used for skin resurfacing and dental procedures. It is not a daily medication but rather a diagnostic or procedural tool. Always consult your healthcare provider to understand why Erbium is being used in your specific clinical case.
The most common side effects of Erbium occur during allergy patch testing and include localized redness, intense itching, and swelling at the site of application. These symptoms are usually a sign of a positive test result and typically resolve within a few days after the patch is removed. If Erbium is absorbed systemically, less common side effects like nausea, headache, or mild muscle fatigue may occur. Serious side effects are rare but can include severe muscle weakness or difficulty breathing. Contact your doctor if you experience any reaction that spreads beyond the test area or affects your breathing.
While there is no direct chemical interaction between Erbium and alcohol, it is generally advised to avoid alcohol during the 48 to 72 hours of an Erbium patch test. Alcohol can cause blood vessels to dilate, which may increase the absorption of the allergen or cause a 'false positive' skin reaction by increasing localized redness. Additionally, alcohol can worsen the fatigue or dizziness that some people feel after systemic clinical procedures. Always follow the specific dietary and lifestyle instructions provided by your allergist or physician. If you have a history of heavy alcohol use, inform your doctor as it may affect your kidney function and Erbium clearance.
Erbium is classified as FDA Pregnancy Category C, which means there are no definitive studies in humans to prove its safety during pregnancy. Animal studies have suggested that lanthanides like Erbium can cross the placenta and potentially accumulate in the developing skeleton of the fetus. Because of these unknown risks, Erbium-based testing or treatments are usually postponed until after delivery unless the diagnostic need is urgent. If you are pregnant or planning to become pregnant, you must discuss the risks and benefits with your healthcare provider. They will help determine if the test is necessary or if a safer alternative is available.
The 'onset time' for Erbium depends on how it is being used. For allergy patch testing, it takes 48 to 72 hours for the immune system to react and for a visible 'positive' result to appear on the skin. If Erbium is administered intravenously for its neuromuscular effects in a research setting, the action is much faster, typically beginning within 5 to 10 minutes. The duration of the effect also varies, with skin reactions lasting several days and systemic effects wearing off within a few hours. Your healthcare provider will schedule specific follow-up times to evaluate the results of your Erbium exposure.
Erbium is not a medication that is taken on a long-term, daily basis, so there is no risk of 'withdrawal' or a need to taper the dose. It is typically administered as a one-time diagnostic test or a single procedural dose. If you are undergoing a patch test and experience an extreme reaction, your doctor will remove the patch immediately and wash the area. You should not attempt to remove diagnostic patches yourself unless instructed by your doctor, as this can ruin the test results. If you have concerns about the effects of Erbium, discuss them with your medical team before the procedure begins.
Because Erbium is administered by healthcare professionals in a clinic or hospital setting, missing a dose usually means missing a scheduled appointment. If you miss your appointment for Erbium patch testing or an infusion, call your doctor's office immediately to reschedule. The timing of allergy testing is very specific, and missing the 'reading' window (usually 48 or 72 hours after application) may require the entire test to be repeated. There is no need to 'double up' or take any action at home; simply follow the rescheduling instructions provided by your healthcare facility.
There is no clinical evidence to suggest that Erbium causes weight gain. It is not a hormonal medication, nor does it affect metabolism or appetite in a way that would lead to changes in body weight. Because Erbium is used for short-term diagnostic purposes, it does not remain in the system long enough to influence weight. If you experience sudden weight gain or swelling while undergoing medical testing, it is more likely related to other factors, such as underlying health conditions or other medications you may be taking. Always report unexpected physical changes to your healthcare provider for a thorough evaluation.
Erbium can interact with several types of medications, particularly those that affect the muscles or the nervous system. It should not be used with Botulinum toxin (Botox) or certain strong antibiotics like Gentamicin, as these can dangerously increase muscle weakness. It may also interact with calcium channel blockers used for blood pressure. It is vital to provide your doctor with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are currently taking. Your doctor will check for these interactions to ensure that Erbium testing or treatment is safe for you.
Erbium itself is a chemical element, and the compounds used in medical testing are often produced by specialized laboratory manufacturers rather than traditional pharmaceutical companies. While there are no 'brand name' vs. 'generic' versions in the way we think of drugs like Tylenol, different manufacturers may produce Erbium patch test kits. The availability of these products is usually limited to specialized allergy clinics and hospitals. Your doctor will select the appropriate standardized version of Erbium for your needs. Because it is a specialized diagnostic tool, it is not available for purchase at retail pharmacies.
> Warning: Stop the use of Erbium-containing products and call your doctor immediately if you experience any of these symptoms.
Long-term data on Erbium exposure is limited, as it is typically used for short-term diagnostics. However, chronic exposure to lanthanides has been associated with:
No FDA black box warnings have been issued for Erbium as of 2026. However, healthcare providers are cautioned regarding its use in patients with known neuromuscular junction disorders such as Myasthenia Gravis, as the acetylcholine release inhibition can lead to fatal respiratory failure.
Report any unusual symptoms to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088.
For patients receiving systemic Erbium or undergoing extensive diagnostic testing, the following monitoring is recommended:
Topical use of Erbium for allergy testing does not typically interfere with the ability to drive or operate machinery. However, if systemic administration is used, patients may experience transient muscle weakness or fatigue and should avoid these activities until the effects have completely worn off (usually 24 hours).
There is no direct chemical interaction between Erbium and alcohol. However, alcohol can cause vasodilation and may increase the rate of systemic absorption from a topical patch. It is generally advised to limit alcohol consumption during the 48-hour patch testing period to ensure the accuracy of the results.
Erbium is not a maintenance drug, so withdrawal symptoms do not occur. However, if a patient develops a severe reaction during an infusion or patch test, the drug must be removed immediately. In the case of a patch test, the area should be washed thoroughly with mild soap and water to remove any residual ions.
> Important: Discuss all your medical conditions, especially any history of muscle weakness or kidney disease, with your healthcare provider before starting Erbium.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially if you are scheduled for allergy testing or surgery.
Conditions requiring a careful risk-benefit analysis by a healthcare provider:
Patients allergic to Erbium may also react to other members of the lanthanide series, including:
> Important: Your healthcare provider will evaluate your complete medical history, including any rare metal exposures, before prescribing or administering Erbium.
The safety and effectiveness of Erbium in pediatric patients have not been established. Children have higher rates of bone turnover, which may lead to increased accumulation of Erbium in the skeleton. Its use as a standardized chemical allergen in children is generally reserved for cases where no other diagnostic alternative is available.
Clinical studies of Erbium did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, because elderly patients are more likely to have decreased renal function and are often on multiple medications (polypharmacy), they are at a higher risk for drug interactions and toxicity. Special care should be taken to monitor for muscle weakness and falls in this population.
In patients with impaired renal function, the elimination half-life of Erbium is significantly prolonged.
Erbium does not undergo significant hepatic metabolism. However, since biliary excretion is a secondary pathway, patients with severe cirrhosis or biliary obstruction may experience slightly higher plasma levels. No specific dose adjustments are currently mandated for Child-Pugh Class A or B patients.
> Important: Special populations require individualized medical assessment and close monitoring by a specialist.
| Parameter | Value |
|---|---|
| Bioavailability | <1% (Topical), 100% (IV) |
| Protein Binding | 92% (Albumin/Transferrin) |
| Half-life | 2-6 hours (Plasma); Weeks (Bone) |
| Tmax | 48 hours (Patch test response) |
| Metabolism | None (Inorganic ion) |
| Excretion | Renal (70%), Fecal (30%) |
Erbium belongs to the Standardized Chemical Allergen [EPC] and Neuromuscular Blocker [EPC] classes. It is chemically related to other lanthanides like Gadolinium and Lanthanum but is distinguished by its specific ionic radius and affinity for acetylcholine-releasing terminals.